A high-throughput response to the SARS-CoV-2 pandemic

Four years after the beginning of the COVID-19 pandemic, it is important to reflect on the events that have occurred during that time and the knowledge that has been gained. The response to the pandemic was rapid and highly resourced; it was also built upon a foundation of decades of federally funde...

Full description

Saved in:
Bibliographic Details
Published in:SLAS discovery 2024-07, Vol.29 (5), p.100160, Article 100160
Main Authors: Rasmussen, Lynn, Sanders, Shalisa, Sosa, Melinda, McKellip, Sara, Nebane, N. Miranda, Martinez-Gzegozewska, Yohanka, Reece, Andrew, Ruiz, Pedro, Manuvakhova, Anna, Zhai, Ling, Warren, Brooke, Curry, Aliyah, Zeng, Qinghua, Bostwick, J. Robert, Vinson, Paige N.
Format: Article
Language:English
Subjects:
Antiviral
BSL-3
Coronavirus
COVID
COVID-19
Drug discovery
High-throughput
HTS
MERS
Pandemic
SARS
SARS-CoV
SARS-CoV-2
SARS2
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Four years after the beginning of the COVID-19 pandemic, it is important to reflect on the events that have occurred during that time and the knowledge that has been gained. The response to the pandemic was rapid and highly resourced; it was also built upon a foundation of decades of federally funded basic and applied research. Laboratories in government, pharmaceutical, academic, and non-profit institutions all played roles in advancing pre-2020 discoveries to produce clinical treatments. This perspective provides a summary of how the development of high-throughput screening methods in a biosafety level 3 (BSL-3) environment at Southern Research Institute (SR) contributed to pandemic response efforts. The challenges encountered are described, including those of a technical nature as well as those of working under the pressures of an unpredictable virus and pandemic.
ISSN:2472-5552
2472-5560
2472-5560
DOI:10.1016/j.slasd.2024.100160